Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatme...
AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its bloc...
AstraZeneca announced that the CAPItello-290 Phase 3 trial for Truqap (capivasertib) combined with paclitaxel in advanced or me...
Nurix Therapeutics presented updated clinical data for NX-5948, an orally bioavailable BTK degrader, at the EHA Congress. NX-59...
AstraZeneca's breakthrough drug, Imfinzi, combined with chemotherapy, has been officially approved by the FDA to treat adva...
AstraZeneca shares data from the ECHO Phase 3 trial on Calquence plus bendamustine and rituximab in untreated mantle cell lymph...
First and only BTK inhibitor to demonstrate favorable overall survival trend vs. standard-of-care chemoimmunotherapy in this se...
-Reuters
